Orexigen Obesity Pill Catching Up With Competitors

Tickers in this article: ARNA OREX VVUS

SAN FRANCISCO (TheStreet) -- Orexigen Therapeutics (OREX) said results from a cardiovascular safety study of its weight-loss pill Contrave could be ready as early as the second quarter. If positive, the company will resubmit the drug for FDA approval in the second half of the year.

Orexigen CEO Michael Narachi provided an update on Contrave at the J.P. Morgan Healthcare Conference on Tuesday.

Contrave could be approved in the first half of 2014. The commercial launch of the weight-loss pill is being handled by Takeda, which has a lot of metabolic drug experience. (Actos is a blockbuster diabetes drug.) This experience could prove beneficial with the Contrave launch.

Orexigen's $488 million market value is significantly lower than its obesity competitors Arena Pharmaceuticals ($2.1 billion market cap) and Vivus ($1.5 billion market cap.) Arena presents at the J.P. Morgan conference later today.

Read a lot more about Orexigen's outlook and the way investors and others reacted to the company's J.P. Morgan presentation on Twitter with this Appeering conversation thread:

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Usage of this site is governed by TheStreet's Terms of Use available here. Information collected on this site may be collected by TheStreet and OC Register. TheStreet's use of information collected on this site will be governed by TheStreet's privacy policy available here. OC Register's use of information collected on this site will be governed by OC Register's privacy policy available here. If either TheStreet's or OC Register's privacy policy have provisions that are more restrictive than the provisions of the other party's privacy policy, such more restrictive provisions shall not apply to such other party.

Copyright © 2012 Orange County Register Communications. All Rights Reserved.
Site Help | Site Map